Nasodine COVID-19 patent granted


• Patent now granted in US, Australia and South Africa

• Patent supports proposed nasal disinfection use of Nasodine

Firebrick Pharma is pleased to announce that our patent covering the use of Nasodine® Nasal Spray in COVID-19 has now been granted in South Africa.

The patent has previously been granted in the US and Australia (innovation patent), and acceptance in other countries is still pending. The patent specifically protects the use of intranasal povidone-iodine as a method of reducing the viral load of SARS-CoV-2 in the nose.

Relevantly, we recently announced the results of our Phase 2 trial in COVID-19 patients, which demonstrated that Nasodine achieved 100% clearance of the SARS-CoV-2 virus from the nasal passages (refer announcement 7 August 2023).

We also recently announced the proposed use of Nasodine in some markets as a nasal antiseptic/disinfectant (refer announcement 15 November 2023).

This patent is very relevant to that use, which includes the elimination of pathogenic viruses from the nose, such as SARS-CoV-2 and any future pandemic virus.